The Union Ministry of Health and Family Welfare has officially issued the Drugs (Eleventh Amendment) Rules, 2026, introducing strict regulatory provisions to debar applicants found submitting misleading, fake, or fabricated documents or information. Published in the Gazette of India via notification G.S.R. 706(E), the new amendments take effect immediately upon their publication to strengthen oversight across the national pharmaceutical sector.
Under the amended framework, a formal definition for “debarment” has been inserted into rule 2 of the Drugs Rules, 1945. It defines debarment as the prohibition, exclusion, or disqualification of any person, firm, or entity from engaging in the import, manufacture, sale, distribution, stock, exhibition, or offer for sale of drugs, for a specified period or permanently, following statutory violations.
To enforce this standard across all operational stages, specific debarment provisions have been integrated into key sections, including rule 29B for import, rule 66B for sales and distribution, alongside rules 84F, 93A, 122DB, 122Q, and 150L. Under these provisions, the relevant Licensing Authority or Central Licensing Approving Authority must afford the applicant an opportunity to show cause in writing before issuing a debarment order.
The rules also establish a fair recourse mechanism, allowing any aggrieved applicant to file an appeal with the government within thirty days of receiving the order. Following necessary inquiries and a formal hearing, the government will pass final orders. Enacted under sections 12 and 33 of the Drugs and Cosmetics Act, 1940, in consultation with the Drugs Technical Advisory Board (DTAB), these measures aim to enforce strict regulatory compliance, uphold documentation integrity, and safeguard India’s pharmaceutical supply chain.
Written by: Pragna Biswas
Graphics by: Pramit Hazra
